]. The median age of patients was 67 years, and CR/CRp rates were 30.4% with a median DOR of 8.2 months. Median OS was 8.8 months with an 18-month OS rate of 50.1% in patients with CR/CRp. It was noted that patients with a lower co-mutational burden had improved CR/CRp rates, but no specific predictive co-mutations were identified. As a follow-up to this study, 34 patients with ND AML and]. The composite CR rate was 42.4% with over 60% of patients maintaining CRc at 1 year.
]. While the role of OLU is not clear considering experience with using IVO, one compelling scenario could be in the setting of IVO resistance throughRecent studies have evaluated the use of IVO or ENA in combination with other frontline therapies in ND AML. A phase 1 study assessed the use of IVO or ENA in combination with 7 + 3 in patients with].
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: NewsMedical - 🏆 19. / 71 Read more »